Renal Cell Carcinoma - Pipeline Review, Q3 2011

Renal Cell Carcinoma - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Renal Cell Carcinoma - Pipeline Review, Q3 2011', provides an overview of the Renal Cell Carcinoma therapeutic pipeline. This report provides information on the therapeutic development for Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma. 'Renal Cell Carcinoma - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Renal Cell Carcinoma.
- A review of the Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Renal Cell Carcinoma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Renal Cell Carcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Renal Cell Carcinoma pipeline depth and focus of Renal Cell Carcinoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Renal Cell Carcinoma Overview
Therapeutics Development
Renal Cell Carcinoma Therapeutics under Development by Companies
Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Renal Cell Carcinoma Therapeutics - Products under Development by Companies
Renal Cell Carcinoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Renal Cell Carcinoma Therapeutics Development
Renal Cell Carcinoma - Therapeutics Assessment
Late Stage Drug Profiles
Renal Cell Carcinoma Therapeutics – Drug Profile Updates
Renal Cell Carcinoma Therapeutics - Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Renal Cell Carcinoma, Q3 2011
Products under Development for Renal Cell Carcinoma – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Bristol-Myers Squibb Company, 2011
Genzyme Corporation, 2011
Johnson & Johnson, 2011
F. Hoffmann-La Roche Ltd., 2011
Kyowa Hakko Kirin Co., Ltd., 2011
Abbott Laboratories, 2011
Amgen Inc., 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
Seattle Genetics, Inc., 2011
Merck & Co., Inc., 2011
Emergent BioSolutions Inc., 2011
Oxford BioMedica plc, 2011
Micromet, Inc., 2011
Novo Nordisk A/S, 2011
Novartis AG, 2011
Astellas Pharma Inc., 2011
Eisai Co., Ltd., 2011
OSI Pharmaceuticals, Inc., 2011
Pfizer Inc., 2011
SuperGen, Inc., 2011
Taiho Pharmaceutical Co., Ltd., 2011
Exelixis, Inc., 2011
Celgene Corporation, 2011
Bayer AG, 2011
MannKind Corporation, 2011
Merck KGaA, 2011
3SBio Inc., 2011
EntreMed, Inc., 2011
Celldex Therapeutics, Inc., 2011
Active Biotech AB, 2011
AEterna Zentaris Inc., 2011
MethylGene Inc, 2011
Bionomics Limited, 2011
Flamel Technologies S.A., 2011
Beth Israel Deaconess Medical Center, 2011
Pharmacyclics, Inc., 2011
Dendreon Corporation, 2011
MOLOGEN AG, 2011
OncoTherapy Science, Inc., 2011
Threshold Pharmaceuticals, Inc., 2011
Rexahn Pharmaceuticals, Inc., 2011
Spectrum Pharmaceuticals, Inc., 2011
Antisense Pharma GmbH, 2011
Wilex AG, 2011
immatics biotechnologies GmbH, 2011
Curacyte AG, 2011
Argos Therapeutics, Inc., 2011
Cytheris SA, 2011
AgrenVec, S.L., 2011
Gene Signal International SA., 2011
MacroGenics, Inc., 2011
Pivotal BioSciences, Inc., 2011
Jennerex Biotherapeutics, Inc., 2011
Endocyte, Inc., 2011
Pharminox Limited, 2011
Immutep S.A., 2011
Tigris Pharmaceuticals, Inc., 2011
AVEO Pharmaceuticals, Inc., 2011
KAHR medical Ltd., 2011
Advanced Cancer Therapeutics, 2011
n.v. BRUCELLS s.a., 2011
Agennix AG, 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Renal Cell Carcinoma Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Renal Cell Carcinoma, Q3 2011
Products under Development for Renal Cell Carcinoma – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Discovery and Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011